Posted by Michael Wonder on 22 Jun 2020
‘Pfizer’s Vyndaqel, Vyndamax do not deserve rare disease pricing’
22 June 2020 - Pfizer’s Vyndaqel and Vyndamax -- containing tafamidis to treat cardiomyopathy caused by transthyretin amyloidosis (ATTR-CM) -- do not deserve a rare disease pricing which is too high to help patients, a research team claimed.
On Wednesday, JAMA Cardiology published a research letter, “Initial Experience Prescribing Commercial Tafamidis, the Most Expensive Cardiac Medication in History.”
In the letter, the research team at the Oregon Health & Science University and the University of Pittsburgh said tafamidis, authorized for the treatment of ATTR-CM in May in the U.S., proved to reduce the risk of all-cause death and cardiovascular hospitalisation.
